Fig. 7

Irisin inhibits GCs inflammasome activation and fibrosis. GCs were treated with DHT, in the presence or absence of irisin. A The expression of ASC and GSDMD in GCs was assessed by qRT-PCR. B The expression of NLRP3 inflammasome activation factors (GSDMD, GSDMD-C, ASC, IL-1β and IL-18) in GCs was analyzed by western blot assay. C-D The protein levels of NLRP3 (C) and ASC (D) in GCs were analyzed by immunofluorescence staining (60 ×). (E) The expression of TGF-β and β-catenin in GCs was assessed by qRT-PCR. F The expression of fibrosis factors (collagen I, β-catenin, P-SMAD3, α-SMA, TGF-β) in GCs was analyzed by western blot assay. G-H The protein levels of collagen I (G) and α-SMA (H) in GCs were analyzed by immunofluorescence staining (60 ×). Data are shown as the mean ± SD. *p ≤ 0.05, **p ≤ 0.01. Ctrl, control; DHT, dihydrotestosterone; ASC, apoptosis-associated speck-like protein containing a CARD; GSDMD, gasdermin D; GSDMD-C, C-terminal fragment of gasdermin D; IL-1β, interleukin-1β; IL-18, interleukin-18; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DAPI, 4’,6-diamidino-2-phenylindole; NLRP3, NOD-like receptor family pyrin domain containing 3; TGF-β, transforming growth factor-beta; α-SMA, a-smooth muscle actin